Bristol-Myers Squibb strengthens capabilities with evolution of its U.S. geographic footprint
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced important changes to its U.S. geographic footprint that will strengthen capabilities of the company's R&D hubs of world-class science and innovation in Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts while further integrating biologics development with clinical manufacturing at key sites to foster greater speed and collaboration.
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
- Details
- Category: Novartis
Novartis has announced the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology.
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
- Details
- Category: Boehringer Ingelheim
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy based on their lung cancer type, over the use of chemotherapy.(1) Test results to identify EGFR mutations were not available prior to deciding on therapy for nearly one in five (18%*) patients for whom a test was ordered.
Abbott seeks to terminate Alere acquisition
- Details
- Category: Abbott
Abbott (NYSE: ABT) has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement. In the 10 months following the Jan. 30, 2016, signing of the agreement, Alere has suffered a series of damaging business developments, including the government eliminating the billing privileges of a substantial Alere division,
NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
- Details
- Category: Novo Nordisk
Novo Nordisk has announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.(1) Efficacy also remained high for bleeds treated after 4 hours.
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
- Details
- Category: Novartis
Novartis today announced results from the first-ever international survey of patients with myeloproliferative neoplasms (MPNs), specifically myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET), which indicate that the majority of patients living with these MPNs experience a reduced quality of life.
More Pharma News ...
- IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery
- Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant in Germany
- Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
- AstraZeneca takes latest scientific advances in oncology to major US and European congresses
- GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
- Lilly announces top-line results of solanezumab phase 3 clinical trial
- Shire to establish rare disease innovation hub in Cambridge, Mass.